Now showing items 1-3 of 3

    • Clinical development of new drug-radiotherapy combinations. 

      Sharma, RA; Plummer, R; Stock, JK; Greenhalgh, TA; Ataman, O; Kelly, S; Clay, R; Adams, RA; Baird, RD; Billingham, L; Brown, SR; Buckland, S; Bulbeck, H; Chalmers, AJ; Clack, G; Cranston, AN; Damstrup, L; Ferraldeschi, R; Forster, MD; Golec, J; Hagan, RM; Hall, E; Hanauske, A-R; Harrington, KJ; Haswell, T; Hawkins, MA; Illidge, T; Jones, H; Kennedy, AS; McDonald, F; Melcher, T; O'Connor, JPB; Pollard, JR; Saunders, MP; Sebag-Montefiore, D; Smitt, M; Staffurth, J; Stratford, IJ; Wedge, SR; NCRI CTRad Academia-Pharma Joint Working Group (2016-10)
      In countries with the best cancer outcomes, approximately 60% of patients receive radiotherapy as part of their treatment, which is one of the most cost-effective cancer treatments. Notably, around 40% of cancer cures ...
    • Quality assurance guidance for scoring and reporting for pathologists and laboratories undertaking clinical trial work. 

      Robinson, M; James, J; Thomas, G; West, N; Jones, L; Lee, J; Oien, K; Freeman, A; Craig, C; Sloan, P; Elliot, P; Cheang, M; Rodriguez-Justo, M; Verrill, C; UK National Cancer Research Institute (NCRI) Cellular-Molecular Pathology (CM-Path) clinical trials working group (2019-04)
      While pathologists have always played a pivotal role in clinical trials ensuring accurate diagnosis and staging, pathology data from prognostic and predictive tests are increasingly being used to enrol, stratify and randomise ...
    • Radiotherapy Quality Assurance for the CHHiP Trial: Conventional Versus Hypofractionated High-Dose Intensity-Modulated Radiotherapy in Prostate Cancer. 

      Naismith, O; Mayles, H; Bidmead, M; Clark, CH; Gulliford, S; Hassan, S; Khoo, V; Roberts, K; South, C; Hall, E; Dearnaley, D; CHHiP Investigators (2019-09)
      AIMS:The CHHiP trial investigated the use of moderate hypofractionation for the treatment of localised prostate cancer using intensity-modulated radiotherapy (IMRT). A radiotherapy quality assurance programme was developed ...